Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Stories - Archive
Meeting unmet patient needs Our novel biologics address unmet medical needs across the world.
We believe in developing drugs for those who need them, and not only for those who can afford them.
Research saves lives We are accelerating drug innovation and development for companies globally.
Bringing innovative and transformative medicines to global markets at affordable prices.
Committed to Making Insulins Available & Accessible
Biocon Biologics and Viatris Launch SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in U.S. as the First-Ever Interchangeable Biosimilar
Addressing the COVID-19 Pandemic
The Biocon Group addressed the COVID-19 pandemic unitedly with undeterred spirit and unwavering purpose.
The 10-cent answer to diabetes At 10 cents a day, our insulin is a game changer in the developing world.
Despite the capital-intensive nature of insulin production, Biocon has succeeded in expanding access to insulin therapy in India and key global markets by pursuing an innovation strategy that is rooted in affordability.
